Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC
Clinical trial NCT04055493 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04055493
- Sponsor
- Women's Cancer Study Group GmbH
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-02
- Primary completion
- 2027-07-31
- Enrollment
- 1684
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.